New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:49 EDTABMDAbiomed shares overvalued, says Northland Securities
Northland believes Abiomed utilization rates for Impella are going down on both the ImpellaCP and Impella 2.5. The firm said Abiomed's story is now dependent on new site add-ons where utilization rates haven moved and sees risk to shares. The firm rates Abiomed an Underperform with a $14 price target.
News For ABMD From The Last 14 Days
Check below for free stories on ABMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
17:06 EDTABMDTrial results from Abiomed RECOVER RIGHT show survival rate of 73%
Abiomed announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption study of the Impella RP System. The clinical trial results demonstrated a survival rate of 73% in the overall patient population. Overall, the survival rate was 73% in the entire population at 30 days. Cohort A showed a survival rate of 83.3% and Cohort B had a 58.3% survival rate at 30 days.
September 15, 2014
07:21 EDTABMDHeart Failure Society of America to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use